Hunan Yikang Biotechnology Co., Ltd.

Hunan Yikang Biotechnology Co., Ltd. is a large enterprise engaged in the integration of bioengineering research, development, production, and sales, with total assets of nearly 200 million yuan. Its headquarters is located in the China Liuyang International Biomedical Industrial Park, which is a United Nations-approved international biomedical industry base in China. The company has its own R&D institution, GMP-compliant factory buildings, and a large-scale Cordyceps fruiting body cultivation base.
The Guochen Cordyceps developed by the company was the first in the Cordyceps industry to receive U.S. FDA certification, the first to receive a drug and food category award at an APEC (Asia-Pacific Economic Cooperation) meeting, and the first in the Cordyceps industry to obtain six national bio-high-tech patents. It is a project strongly supported by the state and has been listed in the national 'Torch Program.' CCTV Channel 2, CCTV Channel 7, and major media have reported on this project multiple times. The ecological cultivation technology for the company's artificially cultivated Cordyceps is currently at an advanced level. Testing by the Chinese Academy of Sciences shows that the content of its main active ingredient, cordycepin, is as high as 4.28%, which is 2,140 times that of wild Cordyceps, while its price is only about 1/10 that of wild Cordyceps, indicating a very broad market prospect.